ClinicalTrials.gg
CompletedNCT01959529DEVOTEUpdated Jul 24, 2019Results posted

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

A Phase 3 interventional study of insulin degludec and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 446 sites in 20 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-07-24.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7,637
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
Largest of 70
7,637 · median 384
Started
2013
with 7 others
Phase 3
49 of 70
2 open now
Registered
39th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one has the largest enrollment, is one of 8 that started in 2013, is one of 49 in phase 3, and was the 39th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted globally. The aim of this trial is to compare cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 7,637 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Type 2 diabetes - Age above or equal to 50 years with predefined previous cardiovascular disease(s) or renal disease or age above or equal to 60 years with predefined cardiovascular risk factors - (glycosylated ) above or equal to 7.0% or HbA1c below 7.0% and current insulin treatment corresponding to above or equal to 20 U of basal insulin per day - One or more oral or injectable antidiabetic agent(s) Exclusion Criteria: - An acute coronary or cerebrovascular event in the previous 60 days - Planned coronary, carotid or peripheral artery revascularisation - Chronic heart failure (New York Heart Association) class IV - Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell skin carcinoma)

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
7,637 participants (actual)

Study arms

  • Experimental
    Insulin degludec (IDeg)

    All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.

    Drug: insulin degludec

  • Active comparator
    Insulin glargine (IGlar)

    All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.

    Drug: insulin glargine

Interventions

07

What researchers measure

Primary outcomes

  1. Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke

    Time from randomisation to first occurrence of an event adjudication committee (EAC)-confirmed 3-component major adverse cardiovascular event (MACE): cardiovascular death, non-fatal myocardial infarction, or nonfatal stroke. Events with EAC-confirmed onset date between randomisation and individual end of trial were included in the analyses. The number of subjects experiencing first EAC-confirmed MACEs, date between randomisation to the end of trial, both days included were presented. The trial was event driven and planned to last up to a maximum of 60.5 months. The actual trial duration (time from first subject first visit to last subject last visit) was 35.6 months. The maximum trial duration for a single subject was 33.1 months.

    Time frame: From randomisation to individual end of trial date (maximum patient year observation: 2.75 years)

Secondary outcomes

  1. Number of EAC-confirmed Severe Hypoglycaemic Episodes

    Number of severe hypoglycaemic episodes from week 0 to the last assessment (up to 35.6 months). The episode of severe hypoglycaemia is an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. The trial was event driven and planned to last up to a maximum of 60.5 months. The actual trial duration (time from first subject first visit to last subject last visit) was 35.6 months. The maximum trial duration for a single subject was 33.1 months.

    Time frame: From randomisation to individual end of trial (maximum patient year observation: 2.75 years)

  2. Occurrence of at Least One EAC Confirmed Severe Hypoglycaemic Episode Within a Subject (Yes/no)

    Occurrence of at least one EAC-confirmed severe hypoglycaemic episode within a subject from week 0 to the last assessment (up to 35.6 months). The episode of severe hypoglycaemia is an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions.

    Time frame: From randomisation to individual end of trial date (maximum patient year observation: 2.75 years)

  3. Change in Glycosylated Haemoglobin (HbA1c)

    Mean change in HbA1c from week 0 to month 24.

    Time frame: Randomisation to 24 months

08

Results

Posted Nov 17, 2017

Participant flow

The trial was conducted at 438 sites in 20 countries as follows: Algeria: 6; Argentina: 4; Brazil: 10; Canada: 6; Croatia: 5; Greece: 6; India: 26; Italy: 10; Japan: 8; Republic of Korea: 4; Malaysia: 8; Mexico: 7; Poland: 8; Romania: 4; Russian Federation: 20; South Africa: 15; Spain: 6; Thailand: 6; United Kingdom: 8; United States: 271.

Participant flow — Overall Study
MilestoneInsulin DegludecInsulin Glargine
Started38183819
Exposed38093806
Completed37423747
Not completed7672
Withdrew: Adverse event (not hypoglycaemia)01
Withdrew: Lost to follow-up41
Withdrew: Other7068
Withdrew: Hypoglycaemia11
Withdrew: Lack of glycaemic control11

Outcome measures

PrimaryTime From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke

Time from randomisation to first occurrence of an event adjudication committee (EAC)-confirmed 3-component major adverse cardiovascular event (MACE): cardiovascular death, non-fatal myocardial infarction, or nonfatal stroke. Events with EAC-confirmed onset date between randomisation and individual end of trial were included in the analyses. The number of subjects experiencing first EAC-confirmed MACEs, date between randomisation to the end of trial, both days included were presented. The trial was event driven and planned to last up to a maximum of 60.5 months. The actual trial duration (time from first subject first visit to last subject last visit) was 35.6 months. The maximum trial duration for a single subject was 33.1 months.

Time frame:
From randomisation to individual end of trial date (maximum patient year observation: 2.75 years)
Reported as:
Count of participants · Participants
Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke
ParticipantsInsulin DegludecInsulin Glargine
First EAC-confirmed MACE325356
Myocardial infarction (non-fatal)143163
Stroke (non-fatal)6874
Cardiovascular death114119
Statistical analysis
  • Insulin Degludec vs Insulin Glargine · Regression, Cox · p = <0.001 (p value : Refers to one-sided test of HR \>= 1.3 (against Ha: HR\<1.3).) · Hazard ratio (hr): 0.908 · 95% CI 0.781 to 1.055
SecondaryNumber of EAC-confirmed Severe Hypoglycaemic Episodes

Number of severe hypoglycaemic episodes from week 0 to the last assessment (up to 35.6 months). The episode of severe hypoglycaemia is an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. The trial was event driven and planned to last up to a maximum of 60.5 months. The actual trial duration (time from first subject first visit to last subject last visit) was 35.6 months. The maximum trial duration for a single subject was 33.1 months.

Time frame:
From randomisation to individual end of trial (maximum patient year observation: 2.75 years)
Reported as:
Number · Number of severe episodes
Number of EAC-confirmed Severe Hypoglycaemic Episodes
Number of severe episodesInsulin DegludecInsulin Glargine
Number of EAC-confirmed Severe Hypoglycaemic Episodes280472
Statistical analysis
  • Insulin Degludec vs Insulin Glargine · Negative binomial regression · p = <0.001 (p-value : Refers to one-sided test of RR \>= 1.0 (against Ha: RR\<1.0)) · Rate ratio: 0.601 · 95% CI 0.476 to 0.759The model included treatment (IDeg vs IGlar) as a fixed factor and was fitted using the FAS.
SecondaryOccurrence of at Least One EAC Confirmed Severe Hypoglycaemic Episode Within a Subject (Yes/no)

Occurrence of at least one EAC-confirmed severe hypoglycaemic episode within a subject from week 0 to the last assessment (up to 35.6 months). The episode of severe hypoglycaemia is an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions.

Time frame:
From randomisation to individual end of trial date (maximum patient year observation: 2.75 years)
Reported as:
Count of participants · Participants
Occurrence of at Least One EAC Confirmed Severe Hypoglycaemic Episode Within a Subject (Yes/no)
ParticipantsInsulin DegludecInsulin Glargine
Occurrence of at Least One EAC Confirmed Severe Hypoglycaemic Episode Within a Subject (Yes/no)187252
Statistical analysis
  • Insulin Degludec vs Insulin Glargine · Regression, Logistic · p = <0.001 (p-value: Refers to one-sided test of OR \>= 1.0 (against Ha: OR\<1.0)) · Odds ratio (or): 0.729 · 95% CI 0.600 to 0.866The model was logistic regression with log-link function.The model included treatment (IDeg vs IGlar) as a fixed factor and was fitted using the FAS
SecondaryChange in Glycosylated Haemoglobin (HbA1c)

Mean change in HbA1c from week 0 to month 24.

Time frame:
Randomisation to 24 months
Reported as:
Mean · percentage of HbA1c
Change in Glycosylated Haemoglobin (HbA1c)
percentage of HbA1cInsulin DegludecInsulin Glargine
Change in Glycosylated Haemoglobin (HbA1c)-0.86 ± 1.51-0.84 ± 1.57

Adverse events

Collected over The adverse events were considered from the randomisation visit (week 0) to the follow up visit (end of treatment plus at least 30 days). The trial was event driven and planned to last up to a maximum of 60.5 months. The maximum trial duration for a single subject was 33.1 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Degludec—1,473/3,818 (38.6%)0/3,818 (0%)
Insulin Glargine—1,517/3,819 (39.7%)0/3,819 (0%)
Most frequent serious events
Showing 10 of 1,091
Most frequent serious events
EventInsulin DegludecInsulin Glargine
Cardiac failure congestiveCardiac disorders134/3818143/3819
Acute myocardial infarctionCardiac disorders98/3818115/3819
Acute kidney injuryRenal and urinary disorders70/381895/3819
PneumoniaInfections and infestations90/381890/3819
Coronary artery diseaseCardiac disorders80/381889/3819
Angina unstableCardiac disorders87/381879/3819
Myocardial infarctionCardiac disorders48/381866/3819
HypoglycaemiaMetabolism and nutrition disorders64/381849/3819
CellulitisInfections and infestations52/381861/3819
Atrial fibrillationCardiac disorders47/381856/3819

Baseline characteristics

Baseline analysis was based on the full analysis set (FAS), which included all randomised subjects.

Age, Continuous
Age, Continuous(years)Insulin DegludecInsulin GlargineTotal
Mean64.9 ± 7.365.0 ± 7.565.0 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)Insulin DegludecInsulin GlargineTotal
Female142214372859
Male239623824778
HbA1c
HbA1c(percentage of HbA1c)Insulin DegludecInsulin GlargineTotal
Mean8.44 ± 1.638.41 ± 1.678.43 ± 1.65
09

Study locations

446 sites
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35216, United States
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35294, United States
  • Novo Nordisk Investigational Site
    Montgomery, Alabama 36106, United States
  • Novo Nordisk Investigational Site
    Montgomery, Alabama 36109, United States
  • Novo Nordisk Investigational Site
    Gilbert, Arizona 85295, United States
  • Novo Nordisk Investigational Site
    Glendale, Arizona 85308, United States
  • Novo Nordisk Investigational Site
    Litchfield Park, Arizona 85340, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85050, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85704, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85714, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85723, United States
  • Novo Nordisk Investigational Site
    Little Rock, Arkansas 72205-5446, United States
  • Novo Nordisk Investigational Site
    Little Rock, Arkansas 72205, United States
  • Novo Nordisk Investigational Site
    Searcy, Arkansas 72143, United States
  • Novo Nordisk Investigational Site
    Chula Vista, California 91910, United States
  • Novo Nordisk Investigational Site
    Concord, California 94520, United States
  • Novo Nordisk Investigational Site
    Downey, California 90242, United States
  • Novo Nordisk Investigational Site
    Duarte, California 91010, United States
  • Novo Nordisk Investigational Site
    Encino, California 91436, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    Greenbrae, California 94904, United States
  • Novo Nordisk Investigational Site
    Huntington Beach, California 92648, United States
  • Novo Nordisk Investigational Site
    Inglewood, California 90301, United States
  • Novo Nordisk Investigational Site
    La Jolla, California 92037, United States
  • Novo Nordisk Investigational Site
    La Mesa, California 91942, United States
  • Novo Nordisk Investigational Site
    Lancaster, California 93534, United States
  • Novo Nordisk Investigational Site
    Long Beach, California 90822, United States
  • Novo Nordisk Investigational Site
    Los Alamitos, California 90720, United States
  • Novo Nordisk Investigational Site
    Mission Hills, California 91345, United States
  • Novo Nordisk Investigational Site
    Montclair, California 91763, United States
  • Novo Nordisk Investigational Site
    Monterey, California 93940, United States
  • Novo Nordisk Investigational Site
    North Hollywood, California 91606, United States
  • Novo Nordisk Investigational Site
    Palm Springs, California 92262, United States
  • Novo Nordisk Investigational Site
    Poway, California 92064, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92111, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92120, United States
  • Novo Nordisk Investigational Site
    San Ramon, California 94583, United States
  • Novo Nordisk Investigational Site
    Santa Ana, California 92704, United States
  • Novo Nordisk Investigational Site
    Sherman Oaks, California 91403, United States
  • Novo Nordisk Investigational Site
    Thousand Oaks, California 91360, United States
  • Novo Nordisk Investigational Site
    Tustin, California 92780, United States
  • Novo Nordisk Investigational Site
    Ventura, California 93003, United States
  • Novo Nordisk Investigational Site
    Vista, California 92083, United States
  • Novo Nordisk Investigational Site
    Westminster, California 92683, United States
  • Novo Nordisk Investigational Site
    Colorado Springs, Colorado 80909, United States
  • Novo Nordisk Investigational Site
    Denver, Colorado 80220, United States
  • Novo Nordisk Investigational Site
    Denver, Colorado 80246, United States
  • Novo Nordisk Investigational Site
    Golden, Colorado 80401, United States
  • Novo Nordisk Investigational Site
    Danbury, Connecticut 06810, United States
  • Novo Nordisk Investigational Site
    Norwalk, Connecticut 06851, United States
  • Novo Nordisk Investigational Site
    Waterbury, Connecticut 06708, United States
  • Novo Nordisk Investigational Site
    Boca Raton, Florida 33433, United States
  • Novo Nordisk Investigational Site
    Boynton Beach, Florida 33472, United States
  • Novo Nordisk Investigational Site
    Bradenton, Florida 34201, United States
  • Novo Nordisk Investigational Site
    Brandon, Florida 33511, United States
  • Novo Nordisk Investigational Site
    Clearwater, Florida 33756, United States
  • Novo Nordisk Investigational Site
    Cooper City, Florida 33024, United States
  • Novo Nordisk Investigational Site
    Fleming Island, Florida 32003, United States
  • Novo Nordisk Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • Novo Nordisk Investigational Site
    Gainesville, Florida 32610, United States
  • Novo Nordisk Investigational Site
    Green Cove Springs, Florida 32043, United States
  • Novo Nordisk Investigational Site
    Hialeah, Florida 33012, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32207, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32216, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33135, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33136, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33155, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33165, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33183, United States
  • Novo Nordisk Investigational Site
    Naples, Florida 34119, United States
  • Novo Nordisk Investigational Site
    New Port Richey, Florida 34652, United States
  • Novo Nordisk Investigational Site
    Orlando, Florida 32806, United States
  • Novo Nordisk Investigational Site
    Panama City, Florida 32401, United States
  • Novo Nordisk Investigational Site
    Ponte Vedra, Florida 32081, United States
  • Novo Nordisk Investigational Site
    Port Charlotte, Florida 33952, United States
  • Novo Nordisk Investigational Site
    Port Orange, Florida 32127, United States
  • Novo Nordisk Investigational Site
    South Miami, Florida 33143, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33619, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33624, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30339, United States
  • Novo Nordisk Investigational Site
    Decatur, Georgia 30033, United States
  • Novo Nordisk Investigational Site
    Dunwoody, Georgia 30338, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, Georgia 30046, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Savannah, Georgia 31406, United States
  • Novo Nordisk Investigational Site
    Honolulu, Hawaii 96814, United States
  • Novo Nordisk Investigational Site
    Idaho Falls, Idaho 83404-7596, United States
  • Novo Nordisk Investigational Site
    Addison, Illinois 60101, United States
  • Novo Nordisk Investigational Site
    Champaign, Illinois 61821, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60607, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60616, United States
  • Novo Nordisk Investigational Site
    Crystal Lake, Illinois 60012, United States
  • Novo Nordisk Investigational Site
    Gurnee, Illinois 60031, United States
  • Novo Nordisk Investigational Site
    Hines, Illinois 60141, United States
  • Novo Nordisk Investigational Site
    Springfield, Illinois 62702, United States
  • Novo Nordisk Investigational Site
    Springfield, Illinois 62711, United States
  • Novo Nordisk Investigational Site
    Brownsburg, Indiana 46112, United States
  • Novo Nordisk Investigational Site
    Evansville, Indiana 47714, United States
  • Novo Nordisk Investigational Site
    Franklin, Indiana 46131, United States
  • Novo Nordisk Investigational Site
    Greenfield, Indiana 46140, United States

Showing the first 100 of 446 sites across 20 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Pollock RF, Heller S, Pieber TR, Woo V, Gundgaard J, Hallen N, Luckevich M, Tutkunkardas D, Zinman B; DEVOTE Study Group. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). Diabetes Obes Metab. 2019 Jul;21(7):1706-1714. doi: 10.1111/dom.13730. Epub 2019 Apr 14. PubMed 30924579 ↗
  • Pollock RF, Valentine WJ, Marso SP, Andersen A, Gundgaard J, Hallen N, Tutkunkardas D, Magnuson EA, Buse JB; DEVOTE study group. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). Appl Health Econ Health Policy. 2019 Oct;17(5):615-627. doi: 10.1007/s40258-019-00494-3. PubMed 31264138 ↗
  • Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Frandsen KB, Rabol R, Buse JB. Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. Am Heart J. 2016 Sep;179:175-83. doi: 10.1016/j.ahj.2016.06.004. Epub 2016 Jun 18. PubMed 27595693 ↗
  • Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12. PubMed 28605603 ↗
  • Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Lange M, Brown-Frandsen K, Moses A, Ocampo Francisco AM, Barner Lekdorf J, Kvist K, Buse JB; DEVOTE Study Group. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018 Jan;61(1):48-57. doi: 10.1007/s00125-017-4423-z. Epub 2017 Sep 15. PubMed 28913575 ↗
  • Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pratley RE, Woo V, Heller S, Lange M, Brown-Frandsen K, Moses A, Barner Lekdorf J, Lehmann L, Kvist K, Buse JB; DEVOTE Study Group. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2018 Jan;61(1):58-65. doi: 10.1007/s00125-017-4422-0. Epub 2017 Sep 15. PubMed 28913543 ↗
  • Pollock RF, Valentine WJ, Marso SP, Gundgaard J, Hallen N, Hansen LL, Tutkunkardas D, Buse JB; DEVOTE Study Group. DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK. Diabetes Ther. 2018 Jun;9(3):1217-1232. doi: 10.1007/s13300-018-0430-4. Epub 2018 Apr 30. PubMed 29713962 ↗
  • Theilgaard H, Mollerup I, Helmark IC, Endahl L, Hoskin S, Hvelplund A, Amby LK, Moses AC. Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events). Ther Innov Regul Sci. 2019 Mar;53(2):279-286. doi: 10.1177/2168479018776943. Epub 2018 May 24. PubMed 29793353 ↗
  • Brown-Frandsen K, Emerson SS, McGuire DK, Pieber TR, Poulter NR, Pratley RE, Zinman B, Ranthe MF, Gron R, Lange M, Moses AC, Orsy P, Buse JB; DEVOTE Study Group. Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). Diabetes Obes Metab. 2019 Jun;21(6):1437-1444. doi: 10.1111/dom.13677. Epub 2019 Apr 1. PubMed 30793465 ↗
  • Pratley RE, Emerson SS, Franek E, Gilbert MP, Marso SP, McGuire DK, Pieber TR, Zinman B, Hansen CT, Hansen MV, Mark T, Moses AC, Buse JB; DEVOTE Study Group. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). Diabetes Obes Metab. 2019 Jul;21(7):1625-1633. doi: 10.1111/dom.13699. Epub 2019 Apr 15. PubMed 30850995 ↗
  • Klein KR, Franek E, Marso S, Pieber TR, Pratley RE, Gowda A, Kvist K, Buse JB. Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE. BMJ Open Diabetes Res Care. 2021 Nov;9(2):e002339. doi: 10.1136/bmjdrc-2021-002339. PubMed 34819298 ↗
  • Amod A, Buse JB, McGuire DK, Pieber TR, Pop-Busui R, Pratley RE, Zinman B, Hansen MB, Jia T, Mark T, Poulter NR; DEVOTE Study Group. Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). Diab Vasc Dis Res. 2020 Nov-Dec;17(6):1479164120970933. doi: 10.1177/1479164120970933. PubMed 33280425 ↗
  • Heller S, Lingvay I, Marso SP, Philis-Tsimikas A, Pieber TR, Poulter NR, Pratley RE, Hachmann-Nielsen E, Kvist K, Lange M, Moses AC, Andresen MT, Buse JB; DEVOTE Study Group. Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE. Diabetes Obes Metab. 2020 Dec;22(12):2241-2247. doi: 10.1111/dom.14049. Epub 2020 Jul 9. PubMed 32250536 ↗
  • Pratley RE, Husain M, Lingvay I, Pieber TR, Mark T, Saevereid HA, Moller DV, Zinman B; DEVOTE Study Group. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol. 2019 Nov 15;18(1):156. doi: 10.1186/s12933-019-0960-8. PubMed 31729990 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Oct 2016, 35 months.

Results were first posted in Nov 2017, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 35 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2013
First posted
Oct 10, 2013
StartActual
Oct 29, 2013
Primary completionActual
Oct 16, 2016
CompletionActual
Oct 16, 2016
Results first posted
Nov 17, 2017
Last update
Jul 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01959529
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 10, 2013
Start date
Oct 29, 2013
Primary completion
Oct 16, 2016
Completion
Oct 16, 2016
Results posted
Nov 17, 2017
Last update
Jul 24, 2019

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin degludec

Start the discussion